Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 1—January 2011
Dispatch

Serotype Distribution and Drug Resistance in Streptococcus pneumoniae, Palestinian Territories

Randa Kattan, Amal Abu Rayyan, Inas Zheiman, Suzan Idkeidek, Sabri Baraghithi, Nabeel Rishmawi, Sultan Turkuman, Afaf Abu-Diab, Riyad Ghneim, Madeleine Zoughbi, Rula Dauodi, Raed Ghneim, Abed-El-Razeq Issa, Issa Siryani, Randa Al Qas, Rawan Liddawi, Hatem Khamash, Moein Kanaan, Hiyam Marzouqa, and Musa Y. HindiyehComments to Author 
Author affiliations: Author affiliations: Caritas Baby Hospital, Bethlehem, Palestinian Territories, West Bank (R. Kattan, N. Rishmawi, S. Turkuman, A. Abu-Diab, Riyad Ghneim, M. Zoughbi, R. Dauodi, Raed Ghneim, A.-E.-R. Issa, I. Siriani, R. Al Qas, R. Lidawi, H. Marzouqa, M.Y. Hindiyeh); Bethlehem University, Bethlehem (A. Abu Rayan, M. Kanaan, M.Y. Hindiyeh); Maqassed Islamic Hospital, East Jerusalem, Palestinian Territories (I. Zheiman, S. Idkeidk, S. Barghithi, H. Khamash)

Main Article

Table A1

Distribution of Streptococcus pneumoniae serotypes and antimicrobial susceptibility patterns, Palestinian Territories, West Bank*

Serotype No. (%) isolates Penicillin, %
 Cefotaxime, %
 Co-trimoxazole, %
 Erythromycin, %
 Ofloxacin, %
 Vancomycin, %
S I R S I R S I R S I R S I R S I R
6A/B 17 (14.2) 100 0 0 100 0 0 52.9 11.8 35.3 47.1 5.9 47.1 100 0 0 100 0 0
14 16 (13.3) 87.5 13.5 0 100 0 0 18.8 6.2 75 25 0 75 87.5 12.5 0 100 0 0
1 14 (11.7) 100 0 0 100 0 0 7.14 35.7 57.1 92.9 7.1 0 100 0 0 100 0 0
9V 11 (9.2) 100 0 0 100 0 0 27.3 18.2 54.6 90.9 0 9.1 100 0 0 100 0 0
5 9 (7.5) 100 0 0 100 0 0 11.1 66.7 22.2 88.9 0 11.1 100 0 0 100 0 0
19F 8 (6.7) 100 0 0 100 0 0 37.5 12.5 50 62.5 0 37.5 100 0 0 100 0 0
4 6 (5.0) 100 0 0 100 0 0 83.3 0 16.7 66.7 16.7 16.7 100 0 0 100 0 0
19A 5 (4.2) 100 0 0 100 0 0 40 20 40 60 20 20 100 0 0 100 0 0
Sg18 5 (4.2) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
3 4 (3.3) 100 0 0 100 0 0 50 0 50 25 25 50 100 0 0 100 0 0
7F 4 (3.3) 100 0 0 100 0 0 0 0 100 50 0 50 100 0 0 100 0 0
8 3 (2.5) 100 0 0 100 0 0 0 66.7 33.3 100 0 0 100 0 0 100 0 0
23F 3 (2.5) 100 0 0 100 0 0 0 0 100 100 0 0 100 0 0 100 0 0
35B 3 (2.5) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
12F 2 (1.7) 100 0 0 100 0 0 50 50 0 100 0 0 100 0 0 100 0 0
16F 2 (1.7) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
33F 2 (1.7) 100 0 0 100 0 0 0 100 100 50 0 50 100 0 0 100 0 0
8 1 (0.8) 100 0 0 100 0 0 100 0 0 0 0 100 100 0 0 100 0 0
17F 1 (0.8) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
38F 1 (0.8) 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0 100 0 0
NT
 3 (2.5)
 100
 0
 0
100
 0
 0
100
 0
 0
100
 0
 0
100
 0
 0
100
 0
 0
Total
 120
 98.3
 1.7
 0
100
 0
 0
38.3
 17.5
 44.2
68.3
 5
 26.7
98.3
 1.7
 0
100
 0
 0
*S, susceptible; I, intermediate; R, resistant; NT, not serotyped. Boldface indicates pneumococcal conjugate valent 13 vaccine serotypes. Susceptibility testing and interpretation guidelines: penicillin MIC by Etest (S<2, I: 4, R>8 μg/mL); cefotaxime MIC by Etest (S<1, I 2, R>4 μg/mL); co-trimoxazole disk diffusion (S>19, I 16–18, R<15 mm); erythromycin disk diffusion (S>21, I 16–20, R<15 mm); ofloxacin disk diffusion (S>16, I 13–15, R<12 mm); vancomycin disk diffusion (>17 mm).

Main Article

Page created: July 08, 2011
Page updated: July 08, 2011
Page reviewed: July 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external